Intellia Therapeutics, Inc. (FRA:38I)
Germany
· Delayed Price · Currency is EUR 7.98
-0.62 (-7.21%)
At close: Dec 5, 2025
Intellia Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
| Revenue | 57.53 | 57.88 | 36.28 | 52.12 | 33.05 | 57.99 | Upgrade
|
| Revenue Growth (YoY) | 33.52% | 59.55% | -30.40% | 57.69% | -43.01% | 34.55% | Upgrade
|
| Cost of Revenue | 409.88 | 466.31 | 435.07 | 419.98 | 229.81 | 150.41 | Upgrade
|
| Gross Profit | -352.35 | -408.43 | -398.79 | -367.86 | -196.75 | -92.41 | Upgrade
|
| Selling, General & Admin | 126.38 | 125.83 | 116.5 | 90.31 | 71.1 | 44.17 | Upgrade
|
| Operating Expenses | 126.38 | 125.83 | 116.5 | 90.31 | 71.1 | 44.17 | Upgrade
|
| Operating Income | -478.73 | -534.26 | -515.29 | -458.16 | -267.85 | -136.58 | Upgrade
|
| Interest & Investment Income | 33.35 | 47.81 | 49.83 | 8.54 | 1.28 | 2.35 | Upgrade
|
| Earnings From Equity Investments | - | - | -15.63 | -11.08 | -1.33 | - | Upgrade
|
| EBT Excluding Unusual Items | -445.38 | -486.46 | -481.09 | -460.7 | -267.89 | -134.23 | Upgrade
|
| Gain (Loss) on Sale of Investments | -0.43 | -32.57 | - | - | - | - | Upgrade
|
| Other Unusual Items | - | - | -0.1 | -13.49 | - | - | Upgrade
|
| Pretax Income | -445.81 | -519.02 | -481.19 | -474.19 | -267.89 | -134.23 | Upgrade
|
| Net Income | -445.81 | -519.02 | -481.19 | -474.19 | -267.89 | -134.23 | Upgrade
|
| Net Income to Common | -445.81 | -519.02 | -481.19 | -474.19 | -267.89 | -134.23 | Upgrade
|
| Shares Outstanding (Basic) | 105 | 99 | 89 | 77 | 71 | 56 | Upgrade
|
| Shares Outstanding (Diluted) | 105 | 99 | 89 | 77 | 71 | 56 | Upgrade
|
| Shares Change (YoY) | 9.22% | 11.35% | 15.33% | 8.57% | 26.63% | 18.50% | Upgrade
|
| EPS (Basic) | -4.25 | -5.25 | -5.42 | -6.16 | -3.78 | -2.40 | Upgrade
|
| EPS (Diluted) | -4.25 | -5.25 | -5.42 | -6.16 | -3.78 | -2.40 | Upgrade
|
| Free Cash Flow | -412.63 | -354.66 | -408.07 | -346.85 | -237.79 | -53.5 | Upgrade
|
| Free Cash Flow Per Share | -3.94 | -3.59 | -4.60 | -4.51 | -3.35 | -0.96 | Upgrade
|
| Gross Margin | - | - | - | - | - | -159.35% | Upgrade
|
| Operating Margin | -832.16% | -923.10% | -1420.51% | -879.04% | -810.37% | -235.51% | Upgrade
|
| Profit Margin | -774.94% | -896.77% | -1326.51% | -909.78% | -810.49% | -231.46% | Upgrade
|
| Free Cash Flow Margin | -717.27% | -612.78% | -1124.94% | -665.46% | -719.41% | -92.25% | Upgrade
|
| EBITDA | -466.25 | -523.98 | -506.32 | -450.59 | -260.96 | -130.27 | Upgrade
|
| EBITDA Margin | - | - | - | - | - | -224.63% | Upgrade
|
| D&A For EBITDA | 12.47 | 10.29 | 8.98 | 7.57 | 6.89 | 6.31 | Upgrade
|
| EBIT | -478.73 | -534.26 | -515.29 | -458.16 | -267.85 | -136.58 | Upgrade
|
| EBIT Margin | - | - | - | - | - | -235.51% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.